Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Deterministic modelling for transmission of Human Papillomavirus 6/11: impact of vaccination.

Ribassin-Majed L, Lounes R, Clemençon S.

Math Med Biol. 2014 Jun;31(2):125-49. doi: 10.1093/imammb/dqt001.

2.

Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).

Siddiqui MA, Perry CM.

Drugs. 2006;66(9):1263-71; discussion 1272-3. Review.

PMID:
16827602
3.

[Vaccination against HPV in adults].

Gil Á.

Rev Esp Quimioter. 2009 Nov;22 Suppl 1:22-5. Review. Spanish. No abstract available.

4.

Human papillomavirus quadrivalent vaccine: a look behind the numbers.

Flaherty DK, Alkhateeb FM.

Ann Pharmacother. 2009 Apr;43(4):740-4. doi: 10.1345/aph.1L483. Review.

PMID:
19276314
5.

Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.

Syrjänen KJ.

Scand J Infect Dis Suppl. 2009;107:3-32. doi: 10.1080/00365540902887730. Review.

PMID:
19408160
6.

Post-licensure monitoring of HPV vaccine in the United States.

Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF.

Vaccine. 2010 Jul 5;28(30):4731-7. doi: 10.1016/j.vaccine.2010.02.019. Review.

PMID:
20188681
7.

Human papillomavirus and the HPV vaccine: are the benefits worth the risks?

Knudtson M, Tiso S, Phillips S.

Nurs Clin North Am. 2009 Sep;44(3):293-9. doi: 10.1016/j.cnur.2009.06.005. Review.

PMID:
19683091
8.

Getting to know human papillomavirus (HPV) and the HPV vaccines.

Smith GD, Travis L.

J Am Osteopath Assoc. 2011 Mar;111(3 Suppl 2):S29-34. Review.

PMID:
21415377
9.

[Diseases caused by human papilloma viruses].

Zollner U, Schwarz TF.

Dtsch Med Wochenschr. 2011 May;136(20):1067-72. doi: 10.1055/s-0031-1275845. Review. German.

PMID:
21560109
10.

A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.

Dunne EF, Datta SD, E Markowitz L.

Cancer. 2008 Nov 15;113(10 Suppl):2995-3003. doi: 10.1002/cncr.23763. Review.

11.

Prevention of recurrent respiratory papillomatosis: role of HPV vaccination.

Freed GL, Derkay CS.

Int J Pediatr Otorhinolaryngol. 2006 Oct;70(10):1799-803. Review.

PMID:
16884786
12.

The prophylactic role for the human papillomavirus quadrivalent vaccine in males.

Yancey AM, Pitlick JM, Forinash AB.

Ann Pharmacother. 2010 Jul-Aug;44(7-8):1314-8. doi: 10.1345/aph.1P017. Review.

PMID:
20501891
13.

The quadrivalent human papillomavirus vaccine: potential factors in effectiveness.

Zonfrillo NJ, Hackley B.

J Midwifery Womens Health. 2008 May-Jun;53(3):188-94. doi: 10.1016/j.jmwh.2007.12.015. Review.

PMID:
18455092
14.

Canadian oncogenic human papillomavirus cervical infection prevalence: systematic review and meta-analysis.

Tricco AC, Ng CH, Gilca V, Anonychuk A, Pham B, Berliner S.

BMC Infect Dis. 2011 Sep 5;11:235. doi: 10.1186/1471-2334-11-235. Review.

15.

Human papillomavirus: current status and issues of vaccination.

Malik H, Khan FH, Ahsan H.

Arch Virol. 2014 Feb;159(2):199-205. Review.

PMID:
24022639
16.
17.

Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective.

Regan DG, Philp DJ, Waters EK.

Sex Health. 2010 Sep;7(3):368-75. doi: 10.1071/SH10006. Review.

PMID:
20719229
18.

Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11.

Bonagura VR, Hatam LJ, Rosenthal DW, de Voti JA, Lam F, Steinberg BM, Abramson AL.

APMIS. 2010 Jun;118(6-7):455-70. doi: 10.1111/j.1600-0463.2010.02617.x. Review.

Items per page

Supplemental Content

Support Center